Our strategy
We develop and support life science to remove the barriers that prevent promising discoveries from reaching people with rare diseases and in global health.
As a self-funded organisation, we use our translational expertise to help people living with rare conditions and address some of the major infection-related threats facing human health. We call these areas ‘Translational Challenges.’ Our existing work spans motor neuron disease, global health, chronic respiratory infection, childhood cancer, and rare diseases.
We collaborate with others already working in these areas to create better tests, treatments and cures by providing investment, expert scientific support and commercialisation advice.
Our Translational Challenges
Each of our Translational Challenges targets a specific area or disease where research has great potential to deliver impact but lacks the translational infrastructure needed to bring discoveries to patients. We bring our science, advice and funding to these challenges, and also work closely with partners to tap into their expertise and capabilities.
Motor Neuron Disease
Our vision is a world where motor neuron disease is preventable and treatable.
Chronic Respiratory Infection
Our vision is improved quality of life for those living with cystic fibrosis and bronchiectasis.
Global Health
Our vision is a world with affordable and accessible solutions to better understand, treat, and prevent infectious diseases.
Rare Disease
Our vision is an ecosystem working together to get discoveries and treatments to rare disease patients faster.
Childhood Cancer
Our vision is to drive life-changing innovations for children with cancer.
Focus on the under-served patient
As an independent, self-funded charity, we can focus on finding solutions to medical challenges that may be overlooked due to their complexity, high-risk nature, or commercial uncertainty.
We’re focused on delivering what patients tell us they most need, whether that’s a transformative new drug, diagnostic, device or digital solution.
There are many organisations and researchers already doing incredible work in these areas. Often, we seek to partner with them. Sometimes, we simply act as a bridge between experts.
Creating a lasting impact
We want to continue creating change for patients and building partnerships, long-term.
That means having a plan in place around our financial sustainability. Part of that is in our funding structure, including our early venture funding.
But we’re also concentrating on developing and retaining talent and building our reputation as a leader in translational science.
Looking for more info about our approach and operations?
Latest news
-
LifeArc joins the REMEDi4ALL Consortium, a pioneering global platform shaping the future of drug repurposing
-
£1million partnership aims to develop new treatments for congenital muscular dystrophy
-
Tribune Therapeutics raises EUR 37 million for next-generation anti-fibrotic therapies